Tove Henriksen Selected Research

Parkinson Disease (Parkinson's Disease)

3/2022	Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson's Disease: Real-World Evidence From G7 Countries.
11/2021	Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications.
6/2021	Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease: A Single-Center, Long-Term Follow-Up Study of the Causes for Discontinuation.
1/2021	Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study.
1/2021	Close relationships in Parkinson´s disease patients with device-aided therapy.
8/2020	Access and Use of Device-Aided Therapies for Parkinson's Disease in Denmark.
1/2019	EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.
1/2018	Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
1/2018	Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease.
12/2016	Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therpy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tove Henriksen Research Topics

Disease

17	Parkinson Disease (Parkinson's Disease) 03/2022 - 01/2011
4	Dyskinesias (Dyskinesia) 01/2018 - 01/2014
2	Dystonia (Limb Dystonia) 11/2018 - 09/2015
1	Tardive Dyskinesia 11/2018
1	Glycogen Storage Disease Type VI (Glycogenosis Type VI) 12/2016
1	Disruptive, Impulse Control, and Conduct Disorders (Kleptomania) 06/2015
1	Pain (Aches) 06/2015
1	Anhedonia 06/2015
1	Hyperhidrosis 01/2011
1	Hallucinations (Hallucination) 01/2011
1	Nocturia 01/2011
1	Illusions (Auditory Illusions) 01/2011
1	Fatigue 01/2011

Drug/Important Bio-Agent (IBA)

11	Apomorphine FDA Link 06/2021 - 01/2011
6	Levodopa (L Dopa)FDA LinkGeneric 01/2021 - 01/2014
3	Pharmaceutical PreparationsIBA 11/2018 - 05/2016
1	Carbidopa (Lodosyn)FDA LinkGeneric 01/2021
1	Antipsychotic Agents (Antipsychotics)IBA 11/2018
1	amsonic acid (DAS)IBA 06/2015
1	ropinirole (Requip)FDA LinkGeneric 06/2015
1	Cabergoline FDA LinkGeneric 06/2015
1	Pramipexole (Mirapex)FDA LinkGeneric 06/2015
1	Dopamine Agonists (Dopamine Agonist)IBA 06/2015

Therapy/Procedure

11	Therapeutics 03/2022 - 01/2011
2	Subcutaneous Infusions 01/2018 - 01/2011
1	Drug Therapy (Chemotherapy) 01/2021
1	Deep Brain Stimulation 01/2021
1	Wearable Electronic Devices 01/2018
1	Injections 12/2016